Diagnostics 13Fs: Quest, LabCorp, Thermo Fisher, Bio-Rad

US-traded diagnostics equities form a distinctive specialty healthcare corner of institutional 13F positioning. Quest Diagnostics (DGX, largest US clinical lab), Laboratory Corporation of America (LH, post-Fortrea CRO spinoff 2023), Thermo Fisher Scientific (TMO, life sciences tools plus emerging emerging diagnostics), Bio-Rad Laboratories (BIO, life sciences plus clinical diagnostics), Danaher (DHR, diagnostics plus life sciences plus emerging emerging post-Envista spinoff plus emerging emerging Veralto water plus product identification spinoff 2023), plus Roche Diagnostics (within RHHBY) anchor the cohort. Multi-year emerging molecular diagnostics growth, oncology testing dynamics, plus emerging emerging liquid biopsy drive distinctive institutional positioning. Reading diagnostics 13F positioning requires understanding the clinical-vs-research framework plus the multi-year dynamics.

The diagnostics business model

Diagnostics companies operate four primary economic engines:

1. Clinical lab economics. Multi-year emerging clinical lab economics drives Quest plus LabCorp operator economics. Multi-year emerging routine clinical lab testing (blood chemistry, hematology, microbiology) plus emerging emerging molecular diagnostics plus emerging emerging genomics plus emerging emerging women's health plus emerging emerging emerging emerging drive multi-year emerging emerging operator economics. Multi-year emerging emerging US clinical lab market $90B+ annually plus emerging emerging Medicare PAMA fee schedule plus emerging emerging emerging emerging Medicare 14-day rule reshape lab economics.
2. Molecular diagnostics growth. Multi-year emerging molecular diagnostics growth drives multi-year emerging operator tailwind. Multi-year emerging genetic testing plus emerging emerging emerging emerging companion diagnostics plus emerging emerging tumor profiling (Foundation Medicine Roche, Caris Life Sciences, Tempus AI, plus emerging emerging Guardant Health) plus emerging emerging hereditary cancer testing plus emerging emerging emerging emerging emerging emerging carrier screening drive multi-year emerging molecular diagnostics TAM.
3. Oncology testing dynamics. Multi-year emerging oncology testing drives multi-year emerging diagnostics revenue. Multi-year emerging Foundation Medicine (Roche) plus emerging emerging Guardant Health Guardant360 liquid biopsy plus emerging emerging Tempus AI plus emerging emerging Natera Signatera MRD plus emerging emerging Exact Sciences Cologuard plus emerging emerging emerging Caris Life Sciences plus emerging emerging emerging emerging Veracyte plus emerging emerging emerging emerging tumor profiling drive multi-year emerging oncology testing TAM expansion.
4. Liquid biopsy emerging. Multi-year emerging liquid biopsy emerging drives multi-year emerging operator strategic positioning. Multi-year emerging ctDNA (circulating tumor DNA) plus emerging emerging Guardant Shield colorectal cancer screening (FDA approved 2024) plus emerging emerging Grail Galleri multi-cancer early detection (post-Illumina divestiture 2024) plus emerging emerging Exact Sciences Oncodetect plus emerging emerging Natera Signatera MRD drive multi-year emerging liquid biopsy adoption.

Major US-traded diagnostics names

Quest Diagnostics (DGX)

Largest US clinical lab plus emerging emerging Health Care Provider plus emerging emerging Consumer plus emerging emerging emerging Diagnostics Information Services plus emerging emerging Jim Davis CEO leadership.

Laboratory Corporation of America (LH)

Diversified clinical lab plus emerging emerging post-Fortrea CRO spinoff (June 2023) plus emerging emerging Labcorp Diagnostics plus emerging emerging Labcorp Biopharma Laboratory Services plus emerging emerging Adam Schechter CEO leadership.

Thermo Fisher Scientific (TMO)

Diversified Life Sciences Solutions plus emerging emerging Analytical Instruments plus emerging emerging Specialty Diagnostics plus emerging emerging Laboratory Products & Biopharma Services plus emerging emerging Marc Casper CEO leadership.

Bio-Rad Laboratories (BIO)

Diversified Life Science (Droplet Digital PCR, ddPCR plus emerging emerging Cell Sciences plus emerging emerging Process Chromatography) plus emerging emerging Clinical Diagnostics (immunology, hematology, plus emerging emerging emerging emerging blood typing) plus emerging emerging Norman Schwartz CEO leadership.

Danaher (DHR)

Diversified Biotechnology (Cytiva, Pall, plus emerging emerging Aldevron post-acquisition) plus emerging emerging Life Sciences (Beckman Coulter, Leica Microsystems, plus emerging emerging emerging others) plus emerging emerging Diagnostics (Beckman Coulter, Cepheid, Leica Biosystems, Radiometer, plus emerging emerging emerging emerging Mammotome) plus emerging emerging post-Veralto (water plus product identification) spinoff (October 2023) plus emerging emerging post-Envista (dental) spinoff (2019) plus emerging emerging Rainer Blair CEO leadership.

Roche Diagnostics (within RHHBY)

Swiss-domiciled diversified Roche Diagnostics plus emerging emerging Foundation Medicine plus emerging emerging emerging Flatiron Health plus emerging emerging in-vitro diagnostics plus emerging emerging tissue diagnostics plus emerging emerging emerging Severin Schwan plus Thomas Schinecker CEO leadership.

How institutional managers position around diagnostics

Three patterns appear across smart-money 13Fs:

Pattern 1: Quality-life-sciences concentration

TMO, DHR-concentrated growth manager positions reflect quality life sciences tools plus emerging emerging diagnostics compounding thesis.

Pattern 2: Clinical-lab positioning

DGX, LH-concentrated active manager positions reflect clinical lab plus emerging emerging molecular diagnostics thesis.

Pattern 3: Specialty positioning

BIO-concentrated active manager positions reflect ddPCR plus emerging emerging clinical diagnostics specialty thesis.

How to read diagnostics 13F positioning

Three rules apply:

Rule 1: Identify segment exposure

Clinical lab vs life sciences tools vs molecular dx have distinct dynamics.

Rule 2: Watch organic revenue growth

Multi-year organic revenue drives operator economics.

Rule 3: Cross-check liquid biopsy adoption

Multi-year liquid biopsy drives long-term TAM.

What diagnostics positioning signals

1. Quality-life-sciences conviction. Concentrated TMO, DHR positions signal quality life sciences thesis.
2. Clinical-lab conviction. Concentrated DGX, LH positions signal clinical lab thesis.
3. Specialty conviction. Concentrated BIO positions signal ddPCR specialty thesis.

For real-time tracking of diagnostics 13F activity, see the institutional signals feed.